🧪 A new liver- and gut-targeted oral drug has shown, in a first clinical trial, its ability to reduce triglycerides and other blood lipids - major risk factors for cardiovascular disease, stroke, and pancreatitis.
Read more: https://go.epfl.ch/502f54